D. M. GRAHAM LABS RECEIVED 10 ANDA APPROVALS IN 1985
Executive Summary
D. M. GRAHAM LABS RECEIVED 10 ANDA APPROVALS IN 1985, the generic mfr. told "The Pink Sheet" in a recent letter. Eight of the approvals were for acetaminophen/butalbital combos, while two covered acetaminophen/hydrocodone products. In addition, the company said that there were eight ANDAs issued in 1985 "for our products in the names of our customers and for which we provided the bulk of the submission." This group includes three approvals for Fisons, two each for Gilbert Labs and Carnrick Labs and one for Mayrand. "Five ANDAs have been issued for our products in the names of our customers but these, by agreement, cannot be disclosed," the letter stated. Calling 1985 "a record year for approvals for D. M. Graham Labs," President Dean Graham, PhD, said that the results are indicative of "how effectively the FDA is currently processing their backlog." The exec noted that in addition to the ANDA approvals, the company received four NDAs during the year. Graham Labs has also apparently improved its standing with FDA inspectors in recent years. An establishment inspection report dated 1982 noted that the firm had "a history of manufacturing and shipping new drugs without approved NDAs or ANDAs and . . . of general manufacturing procedures problems." Reportedly, the company has not received an FDA reg letter since July 1982, however.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth